Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
An immunogenic composition comprising (i) a non-virion influenza virus antigen prepared from a virus grown in cell culture; and (ii) an adjuvant. Preferred adjuvants comprise oil-in-water emulsions.
1. An immunogenic composition comprising:
(i) a purified surface antigen, prepared from a cell culture-grown human influenza virus; and
(ii) an adjuvant comprising an oil-in-water emulsion, wherein the composition is free from chicken DNA, ovalbumin and ovomucoid, and wherein the emulsion includes about 4.3% squalene by weight, about 0.5% polysorbate 80 by weight and about 0.48% sorbitan trioleate by weight and has sub-micron droplets.
2. The composition of claim 1 , comprising purified surface antigens from more than one human influenza virus strain.
3. The composition of claim 2 , wherein the purified surface antigens are prepared from human influenza A virus and human influenza B virus.
4. The composition of claim 1 , wherein the purified surface antigen is from an H1 H2, H3, H5, H7 or H9 influenza A virus subtype.
5. The composition of claim 1 , wherein the composition contains from 0.1 to 20 μg of haemagglutinin per viral strain in the composition.
6. The composition of claim 1 , wherein the composition contains less than 10 ng of cellular DNA from the cell culture host, per 15 μg of haemagglutinin.
7. The composition of claim 1 , wherein the composition includes a 3-O-deacylated monophosphoryl lipid A.
8. A method for preparing an immunogenic composition comprising the steps of combining:
(i) a purified surface antigen, prepared from a cell culture-grown human influenza virus; and
(ii) an adjuvant comprising an oil-in-water emulsion, wherein the composition is free from chicken DNA, ovalbumin and ovomucoid, and wherein the emulsion includes about 4.3% squalene by weight, about 0.5% polysorbate 80 by weight and about 0.48% sorbitan trioleate by weight and has sub-micron droplets.
9. A kit comprising:
(i) a first kit component comprising a purified surface antigen, prepared from a cell culture-grown human influenza virus; and
(ii) a second kit component comprising an adjuvant comprising an oil-in-water emulsion, wherein the first kit component is free from chicken DNA, ovalbumin and ovomucoid, and wherein the emulsion includes about 4.3% squalene by weight, about 0.5% polysorbate 80 by weight and about 0.48% sorbitan trioleate by weight and has sub-micron droplets.
10. An immunogenic composition comprising:
(i) a purified surface antigen, prepared from a cell culture-grown human influenza virus; and
(ii) an adjuvant comprising an oil-in-water emulsion and a tocopherol, wherein the composition is free from chicken DNA, ovalbumin and ovomucoid, and wherein the emulsion includes about 4.3% squalene by weight, about 0.5% polysorbate 80 by weight and about 0.48% sorbitan trioleate by weight and has sub-micron droplets.
11. The composition of claim 10 , wherein the purified surface antigen is from an H1, H2, H3, H5, H7, or H9 influenza A subtype.
12. An immunogenic composition comprising:
(i) a purified surface antigen, prepared from a cell culture-grown virus; and
(ii) an adjuvant comprising an oil-in-water emulsion, wherein the composition is a trivalent vaccine comprising influenza antigens from one H1N1 influenza A strain, one H3N2 influenza A strain and one influenza B strain, wherein the composition is free from chicken DNA, ovalbumin and ovomucoid, and wherein the emulsion includes about 4.3% squalene by weight, about 0.5% polysorbate 80 by weight and about 0.48% sorbitan trioleate by weight and has sub-micron droplets.
13. The composition of claim 1 , wherein the composition is substantially free from thiomersal.
14. The composition of claim 1 , wherein the composition is substantially free from mercurial material.